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ABSTRACT 
 
The CD6 glycoprotein is a lymphocyte surface receptor putatively involved in T-cell 
development and activation. CD6 facilitates adhesion between T-cells and APC 
through its interaction with CD166/ALCAM, and physically associates with the TCR at 
the centre of the immunological synapse. However, its precise role during thymocyte 
development and peripheral T-cell immune responses remains to be defined. Here 
we analyze the in vivo consequences of CD6-deficiency. CD6-/- thymi showed a 
reduction in both CD4+ and CD8+ single-positive subsets, and double-positive 
thymocytes exhibited increased Ca2+ mobilization to TCR-crosslinking in vitro. Bone 
marrow chimera experiments revealed a T-cell autonomous selective disadvantage 
of CD6-/- T cells during development. The analysis of TCR-transgenic mice (OT-I and 
Marilyn) confirmed that abnormal T-cell selection events occur in the absence of 
CD6. CD6-/- mice displayed increased frequencies of antigen-experienced peripheral 
T-cells generated under certain level of TCR signal strength and/or co-stimulation 
such as effector/memory (CD4+TEM, CD8+TCM) and regulatory (Treg) T-cells. The 
suppressive activity of CD6-/- Treg was diminished, and CD6-/- mice presented an 
exacerbated autoimmune response to collagen. Taken together these data indicate 
that CD6 modulates the threshold for thymocyte selection and the generation and/or 
function of several peripheral T-cell subpopulations including Treg cells. 
 
Keywords: T cell development, negative selection, CD6, CD5, ALCAM, T cell 
immune responses, autoimmunity, Treg function. 
 
Abbreviations: ALCAM, Activated-Leukocyte Cell Adhesion Molecule; CIA, 
Collagen-Induced Arthritis; DN, double-negative; DP, double-positive; mAb, 
monoclonal antibody; TCM, central memory T cell; Tconv, conventional T cell; TEC, 
Thymic epithelial cell; TEM, effector/memory T cell; Treg, regulatory T cell. 
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INTRODUCTION 
 
T-cell development is a highly regulated physiological process through which T cells 
acquire competence for antigen recognition and those recognizing self-antigens with 
high affinity are physically deleted before migrating to peripheral lymphoid organs 
(Palmer, 2003). Alterations of such process lead to both defective immune responses 
to foreign antigens or to autoimmunity. Even though the avidity of the TCR for self-
peptide/MHC complexes is a key factor in determining the fate of developing 
thymocytes and the outcome of peripheral T-cell immune responses, concomitant 
signals provided by other lymphocyte surface receptors are known to influence this 
process by increasing or reducing the threshold for TCR signalling (Palmer, 2003). 
One such receptor is CD5 (Soldevila et al., 2011) and this could be also the case for 
the related molecule CD6, since they are highly homologous receptors encoded by 
contiguous genes most likely arising by duplication of a common ancestor. Indeed, 
CD5 associates with the antigen-specific receptor complex and negatively modulates 
its signalling. In turn, the expression levels of CD5 on T-cells reflects the strength of 
TCRr signalling, which reciprocally tunes the threshold of the response. 
CD6 is a 105-130 kD surface glycoprotein expressed on all T cells from early stages 
of their development, but also on some B and NK subsets, BM precursors, and brain 
areas (Santos et al., 2016). The extracellular domain of CD6 comprises three 
Scavenger Receptor Cysteine-Rich extracellular domains, the most membrane-
proximal of which (D3) interacts with the amino-terminal immunoglobulin domain of 
CD166/ALCAM (Activated Leukocyte Cell Adhesion Molecule), a broadly expressed 
cell adhesion molecule (Santos et al., 2016) The structure of CD6 and the binding 
region of ALCAM has recently been resolved (Chappell et al., 2015). In vitro assays 
revealed that such an interaction is critical for optimal T-cell activation and 
proliferative responses (Hassan et al., 2004; Gimferrer et al., 2004; Zimmerman et 
al., 2006). Indeed, when co-crosslinked with anti-CD3 mAb increased proliferation, 
intracellular Ca2+ levels and activation of MAPK in human T cells (Santos et al., 
2016). The CD6 cytoplasmic region is devoid of intrinsic catalytic activity but harbours 
consensus motifs for phosphorylation and association with signal transducing 
effectors. Accordingly, CD6 holds two constitutively phosphorylated Ser clusters 
needed for proper MAPK activation (Bonet et al., 2013), and nine Tyr residues that 
may be phosphorylated upon TCR activation and serve as docking sites for 
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downstream signalling effectors such as Syntenin-1 and SLP-76 (Gimferrer et al., 
2005; Hassan et al., 2006). The latter has been recently confirmed by quantitative 
proteomic analysis of primary mouse T cells (Roncagalli et al., 2014), showing that 
SLP-76 binds to CD6 in a ZAP-70-dependent but LAT-independent manner, and 
placing CD6 as a signalling molecule that contributes to the diversification of TCR 
signals. In this regard, CD6 is well positioned to modulate the TCR signalling since it 
physically associates with the TCR complex and co-localizes with it at the centre of 
the immunological synapse during APC-T cell contacts (Gimferrer et al., 2004; 
Zimmerman et al., 2006). The notion that CD6 behaves as a co-stimulatory molecule 
has been, however, recently challenged by in vitro data showing that it may also act 
as a negative modulator of TCR signalling (Hassan et al., 2006; Oliveira et al., 2011). 
Besides its role in T-cell activation, a single study has also involved CD6 in 
thymocyte survival and selection in mice and humans (Singer et al., 2002). This study 
showed that CD6 surface expression levels increase when double positive (DP) 
thymocytes are selected to become single positive (SP) cells and such increase 
correlates with both expression of the selection marker CD69 and resistance to 
apoptosis.  
All the above in vitro evidences support a putative involvement for CD6 in the 
modulation of thymocyte selection and T lymphocyte activation (Santos et al., 2016). 
However, the lack of proper animal models has hindered further understanding of its 
in vivo role during relevant physiological processes. The present report provides the 
first analysis on the in vivo consequences of CD6-deficiency on T-cell development, 
homeostasis and activation. Our results show that CD6 modulates the threshold for 
negative selection in thymus, and influences the generation and/or function of 
peripheral effector/memory and regulatory (Treg) peripheral T-cells. The functional 
defects associated with CD6-deficiency also result in an exacerbated autoimmune 
response in a model of collagen-induced arthritis (CIA). 
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 RESULTS AND DISCUSSION 
CD6-deficiency impacts normal T-cell development  
The role of CD6 in T-cell development was assessed by generating CD6-/- C57BL/6N 
mice in which exons coding for the extracellular region of CD6 were deleted by 
homologous recombination (Fig 1A). Flow cytometry analysis of LN CD4+ and CD8+ 
T cells from CD6-/- mice showed a complete lack of CD6 surface expression as 
compared to CD6+/+ and CD6+/- littermates (Fig. 1B). Analysis of thymus from sex- 
and age-matched CD6-/- and CD6+/+ littermates showed no significant differences in 
total cell numbers (Fig. 1C, left). Although no differences were found in the frequency 
of NKT (CD161+CD3+) and γδ T (data not shown), as well as of  DP or DN thymocyte 
subsets, a significant decrease was observed for CD4+SP cells (Fig. 1C, middle). A 
detailed analysis of CD8+SP cells showed a reduction in the frequency of mature 
CD8+SP (TCRβ+CD24-) together with an increase in immature CD8+SP (TCRβ-
CD24+) (Fig. 1C, right). These findings suggest the involvement of CD6 in the final 
steps of thymocyte selection. Consistent with that view, CD6 expression correlated 
with that of the positive selection marker CD69 in DP thymocytes (Fig. 1D). A similar 
situation has been documented for CD5, a negative modulator of TCR signaling 
(Tarakhovsky et al., 1995) whose expression is developmentally regulated in a TCR 
signal- and avidity-dependent manner (Azzam et al., 2001). A significant increase in 
the frequency of DP cells undergoing selection (CD69+DP) and a concomitant 
reduction in recently selected CD69+CD4+SP and CD69+CD8+SP was found in CD6-/- 
mice as compared to CD6+/+ mice (Fig. 1E). These results suggest that, rather than a 
defect in positive selection per se, CD6-deficiency triggers an increase in the 
negative selection of CD4+ and CD8+SP cells, the final product of the DP to SP 
transition. 
 
CD6-deficiency impacts peripheral effector/memory and regulatory T-cell 
compartments 
Analysis of spleen and LN from CD6-/- mice revealed total cell numbers (Fig. 2A, left) 
and percentage of T (both CD4+ and CD8+), B (CD19+) (Fig. 2A, right), γδT, NK and 
NKT (data not shown) cells similar to those found in CD6+/+ littermates. Surface 
levels of CD3, CD4, CD8 and CD45 from peripheral CD6-/- T cells were also similar to 
those of CD6+/+ cells (Fig. 2B). However, a slightly reduced CD5 expression was 
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observed on both CD4+ and CD8+ spleen T cells from CD6-/- mice compared to 
CD6+/+ littermates (Fig. 2C). This was also true for thymocytes, from early to late 
maturational stages (Fig. 2C). The intriguing fact is that the analysis of CD5-/- mice 
revealed increased CD6 expression in both CD4+ and CD8+ spleen T cells but not 
thymocytes. These reciprocal changes observed in both CD6-/- and CD5-/- mice 
suggest a functional cross-talk in the regulation of CD6 and CD5 surface expression 
that deserve further exploration. 
Analysis of spleen and LN also revealed that CD6-/- mice present significantly 
increased percentages of effector/memory CD4+ (CD4+TEM, CD44hiCD62Llo) and 
central memory CD8+ (CD8+TCM, CD44hiCD62Lhi) T cells (Fig. 2D). Increased 
percentages of cells with Treg phenotype (CD4+CD25+FoxP3+) were also observed 
(Fig. 2E). Interestingly this increase could not be detected in the thymus, suggesting 
that CD6-deficiency does not affect the generation of thymic Treg cells. Taken 
together, the data indicate that CD6-deficiency favors the expansion of antigen-
experienced peripheral T-cell subsets generated under high TCR-signal strength 
conditions (Lanzavecchia and Sallusto, 2005). 
Increased frequency of effector/memory T cells has been attributed to homeostatic 
proliferation, also known as lymphopenia-induced proliferation (Jameson, 2002). 
Such an increase could result from the decreased thymic output observed in the 
absence of CD6 (Fig. 1C). However, the lower BrdU incorporation observed in 
spleen and LN CD8+TCM and CD4+TEM cells from CD6-/- mice (Fig. 2F), argued 
against the possibility of increased homeostatic proliferation. Instead, the previously 
reported role of CD6-ALCAM interactions in optimizing T-cell activation and 
proliferative responses (Gimferrer et al., 2004; Hassan et al., 2004; Zimmerman et 
al., 2006) could feasibly account for the low in vivo proliferation observed. 
 
T cell-intrinsic mechanisms account for changes in central and peripheral T 
compartments found in CD6-deficient mice 
To determine whether the defect in developing and mature lymphocytes observed in 
CD6-/- mice is T cell-intrinsic, competitive mixed-BM chimera experiments were 
performed. CD3-ε-deficient mice were used as recipients of BM cell mixes (1:1) from 
CD6+/+ (WT45.1) mice with that of CD6-/- (KO45.2) or CD6+/+ (WT45.2) mice (Fig. 
3A). Control mice injected with only CD6+/+ or CD6-/- BM cells showed no significant 
differences in total cell numbers from primary and secondary lymphoid organs (data 
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not shown), indicating that absence of CD6 did not affect BM engraftment and/or 
thymic seeding. In the mixed chimera control group (WT45.2/WT45.1), a competitive 
advantage for CD45.2 cells was observed as visible by CD45.2/CD45.1 ratios >1 
(Fig. 3B). However, this advantage was modulated in the experimental group 
(KO45.2/WT45.1), where the CD45.2/CD45.1 ratio was substantially reduced. In the 
thymus, this effect was observed for all major thymocyte developmental subsets, 
though reaching statistical significance only for DN and CD4+SP and CD8+SP. This 
indicates that CD6-/- T cells present a competitive disadvantage from very early 
stages of their development with regard to their CD6+/+ counterparts. In the periphery, 
a significant reduction of CD6-/- SP CD4+ and CD8+ T cells was also apparent in LN 
(Fig. 3C) and spleen (data not shown). Importantly, such a disadvantage was 
restricted to T cells since the percentage of CD6-/- CD45.2 B cells in both the LN (Fig. 
3C) and spleen (data not shown) was not affected as compared to the control 
group. Overall, these results indicate that CD6-deficiency confers a selective 
disadvantage to developing T cells in a cell autonomous manner and that, in a 
competitive setting, the presence of peripheral CD6-/- T cells was also reduced. As 
observed in CD6-/- mice, (Fig. 2D and 2E), increased frequencies of CD6-/- Treg and 
CD8+TCM cells could be detected in peripheral lymphoid organs of KO45.2/WT45.1 
mixed-BM chimeras compared with their CD6+/+ counterparts from control 
WT45.2/WT45.1 mixed chimeras (Fig. 3D), indicating that such phenotypic 
alterations are also T cell-intrinsic. 
 
CD6 sets the threshold for negative selection in the thymus 
The above results suggest that CD6-deficiency alters thymocyte selection by 
lowering the threshold for negative selection and decreasing the number of cells 
reaching the CD4+SP and CD8+SP stage. Considering that TCR repertoire 
readjustments may occur and complicate result interpretation in mice with polyclonal 
T cell populations, we further addressed the role of CD6 in intrathymic T cell section 
using CD6-/- mice where all T cells bear a single specific TCR. For that purpose, CD6-
/- mice were crossed with either OT-I TCR mice, which produces MHC class I-
restricted OVA-specific CD8+ T cells, or with Marilyn mice, whose CD4+ cells are 
MHC class-II restricted for the male HY antigen. CD6-/- OT-I mice showed a reduction 
in the number of thymic CD8+SP cells expressing the TCR transgene, which reached 
statistical significance in peripheral organs (Fig 4A). Interestingly, CD6-/- OT-I mice 
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also showed an increased proportion of peripheral CD8+ TCM cells (CD44hiCD62Lhi), 
compared to their CD6+/+ counterparts (Fig. 4B). Regarding Marilyn mice, female 
CD6-/- showed a reduced number of thymic CD4+SP cells expressing the TCR 
transgene, which again reached statistical significance in spleen and LN (Fig. 4C). 
Taken together these data indicate that CD6 regulates TCR signaling on developing 
and antigen-experienced T cells. 
This result is reminiscent of the well-acknowledged negative regulatory role of CD5 in 
T-cell development and activation (Tarakhovsky et al., 1995). The CD5 receptor is 
closely related to CD6 both structurally and genetically (Soldevila et al., 2011) and its 
expression is developmentally regulated by TCR avidity, contributing to the fine 
tuning of TCR signalling (Azzam et al., 2001). Consequently, CD5 surface levels on 
thymocytes and peripheral T cells parallel the avidity of their TCRs, as demonstrated 
by the higher levels of Nur-77 found in CD5hi peripheral T cells compared to CD5lo 
(Fulton et al., 2015). Nur-77 levels are considered a sensitive readout of TCR 
signaling strength and are also found elevated in CD6hi peripheral T cells compared 
to CD6lo counterparts (Fig 4D), further supporting the role of CD6 as a putative 
negative regulator under high avidity TCR conditions. 
 
Influence of CD6-deficiency on TCR complex-induced responses from 
developing T cells 
The fate of developing thymocytes is determined by the TCR signal strength resulting 
from interaction with MHC-self peptide complexes presented by thymic APCs 
(Palmer, 2003). Such a signal is negatively modulated by CD5, and as a 
consequence CD5-/- T cells are hyper-responsive to TCR-crosslinking (Tarakhovsky 
et al., 1995). The analysis of TCR-induced Ca2+ flux  showed that CD6-/-, similar to 
CD5-/-, displayed higher intracellular [Ca2+] than CD6+/+ cells (Fig. 5A). Further 
analyses showed that CD6-/- DP but not CD4+SP nor CD8+SP were responsible for 
the increased Ca2+ responses observed (Fig. 5B). Consistent with this, no 
differences in Ca2+ responses were observed for spleen CD4+ or CD8+ T cells from 
CD6-/- and CD6+/+ mice (data not shown). The increased Ca2+ responses observed in 
CD6-/- DP thymocytes could not be attributed to the partial CD5 downregulation 
observed in these cells, since Ca2+ fluxes from CD5+/- mice, which display similar 
CD5 surface levels to those observed in CD6-/- (Fig. 5C, left), did not differ from 
those observed with CD6+/+ thymocytes (Fig. 5C right). Moreover, CD5+/- mice did 
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not show other alterations found in CD6-/- mice such as reduced frequency of thymic 
CD4+SP cells or increased of peripheral CD8+TCM cells (Fig. 5D). Thus, the 
phenotype observed for CD6-/- mice, in terms of Ca2+ flux, decrease in thymocyte 
maturation and increase of memory phenotype in the periphery, is due to CD6-
deficiency and not to the reduced expression of CD5. 
 
Increased peripheral CD4+ proliferative responses, low Treg suppressive 
activity and exacerbated autoimmune response in CD6-/- mice 
Overall, Ca2+ measurements indicate that CD6 behaves as a negative regulator of 
TCR signaling in immature (DP) but not mature (SP) thymocytes nor peripheral T 
cells. However, in vitro CD3-mediated stimulation of CD6-/- CD4+ and CD8+ 
peripheral T cells resulted in slightly increased proliferative responses, which reached 
statistical significance for CD4+ cells (Fig. 6A) but disappeared under CD28 co-
stimulatory conditions. In contrast, CD5-/- T cells, used for comparative purposes, 
showed significant higher proliferative responses under both stimulatory conditions 
(Fig. 6A). This indicates that, under ligand-independent conditions CD6 has the 
capacity of negatively regulating T cell activation. However, it should be mentioned 
that under ligand-dependent conditions (e.g., MLR) the missing CD6-ALCAM 
interaction could result in suboptimal cell-to-cell contacts and net lower proliferative 
responses of CD6-/- T cells (our unpublished observations). 
The increased proportion of peripheral Treg cells led us to assess their functional 
status. As shown in Fig. 6B, CD6-/- spleen CD4+CD25+ T cells exhibited lower 
suppressive activity in vitro as compared to CD6+/+ counterparts, indicating that CD6 
expression is required for full Treg functionality. These results are in agreement with 
the fact that Treg function has been linked to correct SLP-76-mediated signaling 
(Schmidt et al., 2015), and that CD6 constitutes a key element of the SLP-76 
interactome (Roncagalli et al., 2014). Thus, CD6-deficiency would prevent Treg from 
proper recruitment of SLP-76, an essential signaling effector for their function. 
To further explore the possibility that CD6-deficiency may result in dysregulated 
immune responses to auto-antigens in vivo as a consequence of defective Treg 
function and/or defective modulation of TCR signaling, we evaluated the susceptibility 
of CD6-/- mice to CIA a well-established model of T-cell mediated autoimmune 
disease resembling rheumatoid arthritis. As illustrated by Fig. 6C, CD6-/- mice 
showed an earlier CIA onset, and a significantly increased CIA incidence and clinical 
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score than their CD6+/+ littermates. This exacerbated CIA form was accompanied by 
a significantly enhanced joint expression of TNF-α and IL-6 transcripts and a reduced 
expression of FoxP3 (Fig. 6D). Increased expression of IL-17A and IL-1β transcripts 
were also observed, but these differences did not reach statistical significance (Fig. 
6D). No differences regarding IFN-γ, IL-10 and TGF-β transcript levels were found 
(data not shown). These results are compatible with CD6 deficiency potentiating an 
induced Th17 autoimmune response to collagen in the context of a dysfunctional 
Treg activity. This is particularly relevant in the light of reports correlating 
polymorphisms in the human CD6 gene with susceptibility to certain autoimmune 
diseases, such as rheumatoid arthritis or multiple sclerosis (Kofler et al., 2016). 
Although the functional consequences of CD6 polymorphism associated to 
rheumatoid arthritis has not been analyzed, carriers of the multiple sclerosis risk 
allele (rs17828933GG) shows altered CD4+ T cell responses and changes in the 
proportion of full-length and CD6ΔD3 isoforms in both CD4+ and CD8+ cells (Kofler et 
al., 2016), but their consequences on disease susceptibility would deserve further 
study. 
 
Concluding remarks 
This study represents the first in vivo characterization of CD6-deficiency. The results 
show that CD6 acts as a negative modulator of TCR-mediated signalling setting the 
threshold for the final steps of T-cell selection and maturation, and likely for 
peripheral T-cell activation. The molecular mechanism/s by which CD6 restrains TCR 
signalling are by now speculative since CD6 signalling pathway is still relatively 
unknown. Given the reported association of CD5 and CD6 at the T cell surface 
(Gimferrer et al., 2003) and the regulatory role of CD6 on CD5 Tyr phosphorylation 
(Castro et al., 2003), CD5 could mediate such a negative effect. This situation would 
be analogous to that reported for CD2, which would transduce inhibitory signals 
through its association with CD5 (Teh et al., 1997; Castro et al., 2002). Alternatively, 
CD6 could directly recruit downstream negative signalling effectors (e.g., protein Tyr 
phosphatases). The possibility that, apart from decreasing the threshold for negative 
selection, the absence of CD6 impacts thymocyte selection in other manners cannot 
be excluded. Indeed, CD6 has been related to resistance to apoptosis in different 
experimental settings. Accordingly, CD6 is up-regulated both in DP cells undergoing 
positive selection and thymocytes resistant to in vitro induced-apoptosis (Singer et 
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al., 2002), and CD6 ligation protects chronic lymphocytic leukemia cells from IgM-
induced apoptosis (Osorio et al., 1997). Moreover, CD6 expression protects leukemic 
T cells from galectin-induced apoptosis (Escoda-Ferran et al., 2014). Thus, further 
investigation into the role of CD6 as a pro-survival protein is required. 
The CD6-ALCAM interaction is certainly a relevant driver of the observed effects on 
T-cell development and peripheral T-cell homeostasis. However, it has been 
observed that interactions between developing thymocytes (CD6+) and TECs 
(ALCAM+) are not sustained by long-term synapses, but rather by transient and 
repeated contacts with different TECs that maintain NFAT transcription and allow 
positive selection (Ebert et al., 2008). According to this model, the interaction CD6-
ALCAM might be somewhat dispensable in the thymus, where the negative role of 
CD6 would be more evident. 
The generation and maintenance of antigen-experienced T cells such as CD4+TEM, 
CD8+TCM and Treg in CD6-/- mice has been linked to a certain level of TCR signal 
strength and/or co-stimulation (Lanzavecchia and Sallusto, 2005). This appropriately 
fits with the view of CD6 as a negative regulator of thymic and peripheral TCR-
mediated signaling. Indeed, absence of CD6 led to increased negative selection in 
the thymus and increased activation in response to self or environmental antigens in 
the periphery as evidenced from expansion of T-cell subsets with memory and 
regulatory phenotypes. These data are reminiscent of those obtained from the 
analysis of CD5-/- mice where expansion of both memory and regulatory (Ordoñez-
Rueda et al., 2009) T-cells are also observed. Thymic generation of Treg cells 
requires high avidity interaction of TCR with self peptide-MHC complexes. 
Accordingly, increased frequency of Treg in thymus and periphery were previously 
reported for CD5-/-mice, the suppressive functionality of which is debatable (Ordoñez-
Rueda et al., 2009; Dasu et al., 2008). However, while increased proportions of Treg 
can be seen in thymus and periphery of CD5-/- mice, they could only be detected in 
peripheral lymphoid organs of CD6-/- mice. This would indicate that CD6 is 
particularly relevant for regulating the generation of extrathymic Treg during immune 
responses, rather than during thymic T cell selection. Furthermore, the ex vivo 
analysis of CD6-/- spleen Treg showed a lower suppressive activity, further indicating 
that CD6 is also relevant to Treg functionality. The in vivo biological meaning of our 
findings is supported by the fact that CD6-/- mice present an exacerbated form an 
inducible autoimmune disease model (CIA). 
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Thus, the CD6-deficient mice described here represent a new and useful tool to fully 
understand the multifaceted mechanisms by which CD6 exerts its regulatory 
functions in different physiological and pathological contexts. Importantly, these mice 
can also provide valuable insights for the CD6-based therapies that are currently 
under assessment for clinically relevant diseases such as psoriasis, rheumatoid 
arthritis, or lymphoproliferative disorders (Hernández et al., 2016). 
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MATERIALS AND METHODS 
 
Mice. CD6-deficient mice were generated in C57BL/6N background following 
previously published methods (Skarnes et al., 2011) through the Mouse Biology 
Program (www.mousebiology.org) at University of California Davis using targeting 
vector DPGS00142_B_G12 from the trans-NIH Knock-Out Mouse Project (KOMP), 
and obtained from the KOMP Repository (www.komp.org). The gene targeting vector 
was designed to delete exons 3-6 from the cd6 gene coding for the 3 SRCR 
extracellular domains and the stalk region. It was successfully used to obtain a 
recombinant ES cell clone (JM8A1.N3) that gave rise to chimerical mice after 
injection into pseudo-pregnant female mice. Following germ-line transmission of the 
mutant allele, denoted as C57BL/6N-Atm1Brd, a homozygous (CD6-/-) colony was 
established. Absence of CD6 protein expression on T cells was confirmed by flow 
cytometry. The CD6-/- mice were viable and fertile, and their lifespan and behaviour 
were equivalent to their WT littermates. CD5-deficient mice (Tarakhovsky et al., 
1995) on C57BL/6 background were kindly provided by Chander Raman (University 
of Alabama). Mice were maintained at the animal facilities of the School of Medicine 
from Universitat de Barcelona under specific pathogen-free conditions.  
CD6-/- and CD6+/+ mice were bred with MHC class I-restricted OVA-specific OT-I 
(Clarke et al., 2000) and MHC class II-restricted male HY-specific Marilyn  (Scott et 
al., 2000) TCR-transgenic lines at the Centre d’Immunologie Marseille-Luminy (CIML, 
France) and maintained in SPF conditions. CD3ε-deficient (CD3εΔ5/Δ5) mice 
displaying thymocyte development arrest at DN3 stage (Malissen et al., 1995) were 
used as hosts in bone marrow chimera experiments were also kept at CIML. All the 
experiments were done in accordance with the guidelines of the Comité Étic 
d’Experimentació Animal from Universitat de Barcelona. Sex- and age-matched (8-12 
weeks) mice were used in all the experiments. 
 
Calcium-flux measurement. Cytosolic Ca2+ signal was determined by two different 
approaches. In the case of fluorescence microscopy assessment of TCR-induced 
store operated calcium release (SOCE) over time, cells were loaded with 4.5 µM 
Fura-2 AM (30 min) as previously described (Carreras-Sureda et al., 2013). Cytosolic 
[Ca2+] increases are presented as the ratio of emitted fluorescence (510 nm) after 
excitation at 340 and 380 nm, relative to the ratio measured prior to cell stimulation 
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(Fura-2 AM ratio 340/380). All experiments were performed at room temperature and 
cells were bathed in a solution containing 140 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 
0.5 mM MgCl2, 5 mM glucose, 10 mM HEPES (300 mosmol/l, pH 7.4). Ca2+ entry 
was achieved using 1 µg/mL of anti-CD3ε mAb (145.2C11; BD Pharmigen), and 
crosslinking was performed using goat anti-armenian hamster IgG (MP Bio). In the 
case of flow cytometry analysis, thymus and spleen cells were loaded for 20 min at 
37ºC with Indo-1 AM (Molecular Probes) and then stained with fluorescent-labeled 
anti-CD4 (RM4-5, PE; BD Biosciences) and anti-CD8 (53-6.7, APC; BD Biosciences). 
Basal fluorescence was recorded with an LSRII-UV (BD Bioscience) before addition 
of 2.5 µg biotinylated anti-CD3 (145.2C11; BD Biosciences). Crosslinking of anti-CD3 
mAb was induced by the addition of streptavidin (10 µg/ml; Pierce). Calcium fluxes 
were determined on gated CD4+ and CD8+ cells. As loading control, cells were 
stimulated with Ionomycin (1 µg/ml; Sigma). 
 
FACS analyses. Cell staining was done with fluorescent-labeled mAbs to CD5 (53-
7.3), CD4 (RM4-5), CD8α (53-6.7), CD24 (M1/69), TCR-Vα2 (B20.1TCR-Vβ6 (RR4-
7), TCRγ (GL-3) and TCRβ (H57-597)l from BD Biosciences; CD62L (MEL-14), 
CD44 (IM7), CD69 (H1.2F3), CD3 (145.2C11), FoxP3 (3G3), from TONBO 
Bioscience; CD25 (PC61.5), CD19 (6D5), CD161 (PK136) and CD6 (OX129), from 
BioLegend; and Nur77 (12.14) from eBioscience, all according to manufacturer’s 
instructions. FACS analyses were done on a LSRII 564 or FACS Canto II system (BD 
Biosciences) using FlowJo software (TreeStar). Cell viability was evaluated either 
with SYTOX Blue (Life Technologies) or Viability dyes 633nm or 405nm (Life 
Technologies). Apoptotic cells were detected by using Annexin V-FITC apoptosis 
detection kit (Immunostep). 
 
Mixed-BM chimeras. Prior to use, eight-week old CD3εΔ5/Δ5 recipient mice received 
one single dose of irradiation (300 rads) to eliminate partially endogenous immune 
cells and to allow efficient engraftment. Mice were then injected i.v. with 2x106 BM 
cells from CD6+/+ (CD45.1) and from CD6-/- (CD45.2) mice, to generate mixed-
chimeras. As control groups, recipient CD3εΔ5/Δ5 mice (CD45.2) were injected with 
4x106 BM cells from either CD6+/+ or CD6-/- mice. Mouse chimeras were kept on 
antibiotic-containing water (0.2% Bactrim; Roche) during the whole experiment and 
euthanized at 12 weeks for FACS analyses on gated CD3+ or B220+ lymphocytes. 
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In vivo BrdU-incorporation assay. For the detection of proliferating cells  in vivo, 
CD6-/- and CD6+/+ littermate mice were administered for one week with BrdU (0.8mg) 
into drinking water, changing water every two days. BrdU+ cells were visualized by 
FACS with BrdU Cell Proliferation Assay Kit (BD Bioscience) following 
manufacturer’s instructions.  
 
In vitro T-cell proliferation and Treg suppression assay. CD4+ and CD8+ T cells 
were negatively-isolated from spleen and LN (Dynabeads; Life Technologies) and 
incubated for 15 min with CellTrace CFSE Cell Proliferation Kit (Life Technologies), 
and then cultured in complete RPMI medium (10% FCS, 10mM HEPES, 1mM 
Sodium pyruvate, 50µM β-Mercaptoethanol, 5mM Penicillin-Glutamine-Streptomycin; 
Lonza) in 96-well plates coated with increasing concentrations of purified anti-CD3 
mAb (145.2C11; TONBO Bioscience) alone or in combination with 1µg/mL soluble 
anti-CD28 mAb (37.51; TONBO Bioscience) for 72 h at 37ºC, 5%CO2. 
For Treg suppression assays, CD4+CD25- (Tconv) and CD4+CD25+ (Treg) T cells 
were electronically sorted from spleen specimens and, upon CFSE-labelling of the 
former, co-cultured for 3 days at different ratios in 96-well plates coated with anti-CD3 
mAb plus soluble anti-CD28. Proliferative responses were analyzed by determining 
the percentage of CFSElo cells by FACS. 
 
Collagen-induced arthritis (CIA). Induction and assessment of CIA was done in 8–
12 week-old male mice as previously described (Postigo et al., 2011). Briefly, mice 
were immunized once at the base of the tail with 150 µg of chicken collagen type II 
dissolved at a concentration of 2 mg/ml in 0.05 M acetic acid and emulsified with CFA 
containing 4 mg/ml of Mycobacterium tuberculosis in a final volume of 150 µl. 
Evaluation of arthritis clinical severity was performed weekly according to a graded 
scale of 0–3 as follows: 0 = no inflammation (normal joint); 1 = detectable local 
swelling and/or erythema; 2 = swelling in >1 joint and pronounced inflammation; 3 = 
swelling of the entire paw and/or ankylosis. Each paw was graded, and the scores 
were summed (with a maximum possible score 12 per mouse). The expression of 
arthritogenic cytokines and FoxP3 in the joints was explored before and 8 weeks 
after CIA-induction by quantitative real time-PCR as described previously (Postigo et 
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al., 2011). Results (in triplicate) were normalized to GAPDH expression and 
measured in parallel in each sample. 
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FIGURE LEGENDS 
 
Fig. 1. Abnormal thymocyte maturation in CD6-/- mice. A) Schematic 
representation of the gene targeting strategy used for generating CD6-/- mice. B) 
Flow cytometry analysis of CD3+CD19- LN T cells from CD6+/+ (solid line), CD6+/- 
(dashed line), and CD6-/- (grey shaded line) mice, stained for CD6 expression (mAb 
OX-129) or unstained as control (FMO, dotted line). C) Total cell numbers in thymi 
(left) from CD6+/+ (open circles) and CD6-/- (grey filled circles) mice. The percentage 
(mean ± SEM) of main thymocyte subsets (middle) and of immature (TCRβ-CD24+) 
and mature (TCRβ+CD24-) CD8+ cells (right) is also shown. D) Contour plot showing 
CD69 and TCRβ expression on gated DP cells from a CD6+/+ mouse. Histograms 
show CD5 (top) and CD6 (bottom) expression on non-selected (CD69-TCRβlo; grey 
line), and positively selected (CD69+TCRβ+; black line) DP cells from CD6+/+ mice. E) 
Left, Representative contour plots showing the percentage of DP, CD4+ SP and CD8+ 
SP cells among total live CD69+ thymocytes in CD6+/+ and CD6-/- mice. Right, 
Percentage (mean ± SEM) of CD69+ cells in CD4+SP, CD8+SP and DP subsets. Each 
dot represents an individual mouse. *p<0.05, **p<0.01, and ***p=0.001 (unpaired t-
test). 
 
Fig. 2. Phenotypical changes in peripheral T cell compartments in CD6-/- mice. 
A) Left, Total cell numbers in LN and spleen from CD6+/+ (open circles) and CD6-/- 
(grey filled circles) mice. Right, Percentage (mean ± SEM) of CD19+ (B), and CD4+ 
and CD8+ (T) cells from spleen and LN. Each dot represents an individual mouse. B) 
Flow cytometry analysis of spleen T cell surface marker expression from CD6+/+ 
(black solid line), CD6+/- (black dashed line) and CD6-/- (grey shaded line) mice. C) 
Flow cytometry analysis of CD5 (top) and CD6 (bottom) expression on CD4+ and 
CD8+ spleen T cells, and DN, DP, CD4+SP, and CD8+SP thymocytes from wild-type 
(black solid line) and deficient (grey shaded line) mice for CD6 (top) and CD5 
(bottom) receptors. FMO (dotted line). D) Left, Representative contour plots showing 
the percentage of CD4+ TEM (CD44hi CD62Llo) and CD8+ TCM (CD44hi CD62Lhi) cells 
from spleen of CD6+/+ and CD6-/- mice. Right, Percentage (mean ± SEM) of CD4+ 
TEM and CD8+ TCM cells in spleen and LN from CD6+/+ (open circles) and CD6-/- (grey 
filled circles) mice. E) Left, Representative contour plots showing the frequency of 
CD25+FoxP3+ in gated CD4+ thymus and spleen cells from CD6+/+ (left) and CD6-/- 
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(right) mice. Right, Percentage (mean ±SEM) of Treg (CD4+CD25+FoxP3+) in 
thymus, spleen and LN from CD6+/+ (open circles) and CD6-/- (grey filled circles) 
mice. F) Left, Representative flow cytometry histograms showing in vivo BrdU 
incorporation into CD8+TCM (top) and CD4+TEM (bottom) spleen cells from CD6+/+ 
(black solid line) and CD6-/- mice (grey shaded line). Right, Dot density graph 
showing percentage (mean ± SEM) of BrdU+ CD8+TCM and CD4+TEM cells in spleen 
and LN from CD6+/+ (open circles) and CD6-/- (grey filled circles) mice. *p<0.05, 
**p<0.01, and ***p<0.001 (unpaired t-test). 
 
Fig. 3. Alterations in central and peripheral T cell compartments in the absence 
of CD6 are cell-intrinsic. A) Schematic representation of competitive mixed-bone 
marrow chimeras experiment performed. B) Dot density graph showing the ratio 
(mean ± SD) between the percentage of CD45.2+ and CD45.1+ cells in DN, DP and 
SP subsets from control (WT45.2/WT45.1; open circles) and index (KO45.2/WT45.1; 
grey filled circles) experimental groups of mixed-bone marrow chimera assays. Each 
dot represents an individual mouse. C) Dot density graph showing the ratio (mean ± 
SD) between the percentage of CD45.2+ and CD45.1+ cells in LN CD3+ CD4+ and 
CD8+ (left) and B220+ (right) cells from the same groups as in B. D) Dot density 
graph showing the percent (mean ± SEM) of CD4+CD25+FoxP3+ T cells (left), 
CD8+TCM cells (middle) and CD4+TEM (right) gated on CD45.1 or CD45.2 cells from 
the KO45.2/WT45.1 group.*p<0.05, **p<0.01, and ***p<0.001 (unpaired t-test). 
 
Fig. 4. Effect of CD6-deficiency on SP subsets from TCR transgenic mice. A) 
Left, Representative contour plots indicating the percentage of CD8+ SP cells from 
CD6+/+ and CD6-/- OT-I TCR transgenic mice. Right, Total CD8+TCRα-2+ cell 
numbers (mean ± SEM) in thymus, spleen and LN from CD6+/+ (open bars) and CD6-
/- (grey filled bars) OT-I mice (n=4 for each genotype). B) Representative contour 
plots showing CD44 and CD62L staining of gated LN CD8+ from CD6+/+ (top) and 
CD6-/- (bottom) OT-I mice. Percentage of single and double positive cells are 
indicated. C) Left, Representative contour plots showing the percentage of CD4+ SP 
cells from male CD6+/+ or CD6-/- Marilyn mice. Right, Total numbers of CD4+TCRβ-6+ 
cells (mean ± SEM) in thymus, spleen and LN from male CD6+/+ (open bars) or CD6-/- 
(grey filled bars) Marilyn mice (n=4 for each genotype). D) Analysis of Nur-77 
expression in CD6hi and CD6lo peripheral T cells. LN cell suspensions from wild-type 
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C57BL/6 mice were surface stained for CD4, CD8, CD5 and CD6, and then 
intracellularly for Nur-77. Top, FACS histograms showing CD6 (left) and CD5 (right) 
expression on pre-gated CD8+ cells. Bottom, FACS analysis of Nur-77 expression 
on gated cells representing the 5-6% with the highest (hi, black solid line) and lowest 
(lo, black dotted line) positivity for CD6 (left) and CD5 (right) expression in CD8+ T 
cells. FMO (grey shaded line), cells unstained for Nur-77. *p<0.05 and **p<0.01 
(unpaired t-test). 
 
Fig. 5. Modulation of TCR-induced responses from CD6-/- developing and 
mature T cells. A) Left, Fluorescence microscopy assessment of SOCE over time in 
Fura-2 AM-loaded thymocytes from CD6+/+ (n=199 cells, open circles), CD6-/- (n=188 
cells, grey filled circles) and CD5-/- (n=198 cells, black filled circles) mice following 
exposure to 145.2C11 mAb (αCD3) and Fc-specific antiserum (αIgG) (n=4 
mice/genotype). Right, SOCE as represented by mean ± SEM of Area Under Curve 
(AUC) from the same experiment. ***p<0.001 (unpaired t-test). B) FACS analysis of 
i[Ca2+] over time in Indo-1 AM-loaded DP, CD8+SP and CD4+SP cells from CD6+/+ 
(black solid line) and CD6-/- (grey solid line) mice exposed to biotinylated 145.2C11 
mAb (αCD3) plus Streptavidin (SAv). Data are representative of three independent 
experiments. C) Left, FACS analysis of CD5 expression on DP thymocytes from 
CD6+/+ (black solid line), CD5+/- (black dashed line), and CD6-/- (grey shaded line). 
Right, FACS analysis of i[Ca2+] over time of Indo-1 AM-loaded DP cells from CD6+/+ 
(black solid line), CD5+/- (black dashed line), CD6-/- (grey solid line) and CD5-/- (grey 
dashed line) mice, upon exposure to αCD3 mAb plus SAv, as assessed in B. D) Dot 
density graphs showing the percentage (mean ± SEM) of major thymocyte subsets 
(left) and of LN CD4+ and CD8+ TEM and TCM subsets (right) from CD5+/- (black filled 
circles) CD6+/+ (open circles), and CD6-/- (grey filled circles) mice. The results shown 
are from one representative of two experiments performed. **p<0.01, and ***p<0.001 
(unpaired t-test). 
 
Fig 6. Effect of CD6 deficiency on peripheral T-cell proliferative responses, 
Treg activity and CIA. A) Proliferative responses of CFSE-labelled CD4+ and CD8+ 
T cells isolated from spleen and LN of CD6+/+ (open circles; n=4-7 mice/point), CD6-/- 
(grey filled circles; n=4-7 mice/point) and CD5-/- (black filled circles; n=3 mice/point) 
cultured for 72 h in the presence of different concentrations of plastic-bound anti-CD3 
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mAb alone (top) or plus soluble anti-CD28 mAb (bottom; 1µg/mL). Shown is the 
percentage (mean ± SEM) of CFSElo in CD4+ and CD8+ cells. **p<0.01 (Two-way 
ANOVA test). Data are cumulative results from four different experiments. B) Top, 
gating strategy used to electronically sort regulatory (Treg, CD4+CD25+) and 
conventional (Tconv, CD4+CD25-) spleen T cells from CD6-/- or CD6+/+ mice. Bottom, 
CFSE-stained Tconv cells from CD6+/+ mice were cultured in anti-CD3 coated plates 
plus soluble anti-CD28 mAb (1μg/mL) in the absence (w/o) or presence of Treg cells 
from CD6-/- or CD6+/+ mice at different ratios. The percentage of CFSElo lymphocytes 
at d3 of culture from one experiment of four performed is shown. *p<0.05 (unpaired t-
test). C) Left, Clinical severity (mean ± SEM) at different wk post-CIA induction. 
Right, Cumulative incidence (percentage of affected mice) at the indicated wk post-
CIA. **p<0.01, ***p<0.001 (two-way ANOVA test followed by Bonferroni post tests).D) 
Quantitative RT-PCR analysis of joint mRNA levels (mean ± SD fold change of 
triplicates) of IL-6, TNFα, FoxP3, IL-1β, IL-17A and IFNγ relative to GAPDH 
expression, before (NI, n=3) and 8 wk post-CIA of CD6+/+ (n=8) and CD6-/- (n=5) 
mice. *p<0.05 (Student’s t-test). 
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